Evaluation of survival outcome and prognostic factors for oral cavity cancer treated with volumetric arc therapy
- PMID: 37740764
- PMCID: PMC11798281
- DOI: 10.1007/s00432-023-05397-4
Evaluation of survival outcome and prognostic factors for oral cavity cancer treated with volumetric arc therapy
Abstract
Purpose: This study aimed to evaluate the survival outcomes and identify prognostic factors for patients with oral cavity cancer (OCC) who underwent adjuvant treatment with volumetric arc therapy (VMAT) using simultaneous integrated boost (SIB).
Methods: Data was collected for post-operated patients of carcinoma of oral cavity who received adjuvant VMAT with SIB between June 2018 and December 2022. The data was entered and analyzed using SPSS software version 20.0. Survival rates were estimated using Kaplan Meier method. To determine survival difference between the groups, log rank test was used. Multivariate analyses were performed with Cox proportional hazard model and p value < 0.05 was considered as significant.
Results: A total of 178 patients were included in the study. The median follow-up period was 26 months (range 3-56 months). The 3-year OS, DFS, and LRC rates were 78% (95% CI 77-79%), 76% (95% CI 74-77%), and 81% (95% CI 80-82%), respectively. Univariate analysis identified age ≥ 50 years, lymph node involvement, extracapsular extension (ECE), and N2-N3 disease as significant adverse prognostic factors for OS, DFS, and LRC. Multivariate analysis confirmed age ≥ 50 years and nodal involvement as independent predictors of worse OS, DFS, and LRC. Additionally, ECE independently affected OS and DFS.
Conclusion: Adjuvant treatment with VMAT using SIBin patients with OCC is effective. Age and nodal involvement had significant impact on LRC, DFSand OS while ECE on DFSand OS.
Keywords: Oral cavity; Prognostic factors; Squamous cell carcinoma; Survival; Volumetric-modulated arc therapy.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
The author(s) declare no competing interests.
Figures




Similar articles
-
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340. Health Technol Assess. 2006. PMID: 16959170
-
Rationality of FIGO 2018 IIIC cervical cancer according to local tumor and pelvic lymph node metastatic extent-a cohort study.BMC Womens Health. 2025 Jul 4;25(1):308. doi: 10.1186/s12905-025-03846-5. BMC Womens Health. 2025. PMID: 40616036 Free PMC article.
-
Postoperative adjuvant chemotherapy in rectal cancer operated for cure.Cochrane Database Syst Rev. 2012 Mar 14;2012(3):CD004078. doi: 10.1002/14651858.CD004078.pub2. Cochrane Database Syst Rev. 2012. PMID: 22419291 Free PMC article.
-
The Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment Outcomes.Int J Gynecol Cancer. 2018 Sep;28(7):1297-1310. doi: 10.1097/IGC.0000000000001306. Int J Gynecol Cancer. 2018. PMID: 30044322
-
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23. Clin Orthop Relat Res. 2024. PMID: 39051924
Cited by
-
Implicating clinical utility of altered expression of PTCH1 & SMO in oral squamous cell carcinoma.J Mol Histol. 2024 Aug;55(4):379-389. doi: 10.1007/s10735-024-10215-3. Epub 2024 Jul 1. J Mol Histol. 2024. PMID: 38954185
References
-
- Bernier J, Domenge C, Ozsahin M et al (2004) European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350(19):1945–1952. 10.1056/NEJMoa032641 - PubMed
-
- Boysen M, Lövdal O, Winther F et al (1992) The value of follow-up in patients treated for squamous cell carcinoma of the head and neck. Eur J Cancer 28:426–430. 10.1016/s0959-8049(05)80068-1 - PubMed
-
- Chao KSC, Ozyigit G, Tran BN et al (2003) Patterns of failure in patients receiving definitive and postoperative imrt for head-and-neck cancer. Int J Radiat Oncol Biol Phys 55(2):312–321. 10.1016/s0360-3016(02)03940-8 - PubMed
-
- Chen WC, Hwang TZ, Wang WH et al (2009) Comparison between conventional and intensity-modulated post-operative radiotherapy for stage III and IV oral cavity cancer in terms of treatment results and toxicity. Oral Oncol 45(6):505–510. 10.1016/j.oraloncology.2008.07.002 - PubMed
MeSH terms
LinkOut - more resources
Full Text Sources
Medical